Outpatient IV Antibiotic Therapy After a History of Missed Follow-Up
A single patient, medically ready for six weeks of outpatient IV therapy. The disagreement is whether reliable home support is enough to send him home on, given his own recent history of not showing up.
Walter N., a 61-year-old man, spent twenty-nine years maintaining the same elementary school building before retiring, and now spends most days raising his two grandchildren, ages six and nine, after his daughter's work schedule made it necessary — a routine he describes as busier than the job he left. Six weeks of worsening low back pain, which he'd attributed to years of custodial lifting and hadn't sought care for, turned out on MRI to be L3-L4 vertebral osteomyelitis with a small epidural phlegmon, without cord compression or need for surgical decompression. Blood cultures and a CT-guided biopsy both grew methicillin-susceptible Staphylococcus aureus, and after a loading course of IV therapy he has clinically stabilized — afebrile, pain improving, inflammatory markers trending down — with a plan for six total weeks of IV ceftriaxone, chosen specifically for its once-daily dosing and long track record as an outpatient parenteral antibiotic therapy agent.
The question dividing the team isn't the drug or the duration, which nobody disputes, but whether Walter should finish those six weeks as an outpatient at all. His daughter, a registered nurse, lives with him and has offered to manage line care and daily dosing, and by every social-support measure he looks like a strong OPAT candidate. What complicates that read is his own history with this hospital system: a chart review turned up three missed outpatient follow-up appointments in the two years before this admission, including one for a previously flagged abnormal chest X-ray that was never revisited until this presentation. UK OPAT good-practice guidance (Chapman et al., Journal of Antimicrobial Chemotherapy, 2019) and the broader outcomes literature it draws on both identify patient engagement and follow-up reliability, not just home support, as real predictors of OPAT success — and Walter's own recent history sits uncomfortably between the two.
The missed appointments themselves have a pattern worth naming rather than treating as one undifferentiated data point: two were during a stretch eighteen months ago when his daughter's work schedule first became unpredictable and childcare gaps meant missing his own care entirely, and the third, the abnormal chest X-ray follow-up, came six months later once the new routine had mostly settled — meaning the disruption that produced the gap may itself have resolved rather than being an ongoing feature of how he manages his own health. That distinction matters for how much weight his history should carry going forward, though nobody on the team is prepared to simply assume it away without some structural safeguard in place regardless of which explanation turns out to be right.
In case management review, planning discharge
Discharge him on OPAT with weekly infectious disease follow-up. He's medically stable, ceftriaxone's once-daily dosing is genuinely OPAT-friendly with no complex infusion pump required, and he has a registered-nurse daughter in the home willing to manage line care directly. The 2019 UK OPAT good-practice guidelines (Chapman et al.) and the outcomes data behind them show comparable safety and efficacy for appropriately selected patients treated at home versus staying in the hospital, and Walter's home support is about as strong as this decision usually gets.
His home support isn't the part I'd question — it's him. Three missed follow-up appointments in two years, including one for an abnormal finding that went unaddressed until it became this admission, is a real pattern, not a coincidence. The same OPAT literature Chapman draws on identifies patient engagement and follow-up reliability as independent predictors of success, separate from home support — and his own recent history is the specific thing that literature is describing. I'd rather complete more of this course inpatient, where a missed dose or a line problem gets caught the same day, than send him home on the strength of his daughter's availability alone.
The adherence history is real and I wouldn't wave it away — but the fix for it isn't necessarily keeping him inpatient for six weeks, which has its own real cost in nosocomial risk and disruption to the grandchildren he's raising.
Discharge on OPAT, but build in a structured safeguard specifically targeted at what the history actually shows: weekly in-person infectious disease clinic visits rather than phone check-ins, plus an early two-week labs and line-site check rather than waiting for the standard four-week interval. That directly answers the follow-up-reliability concern instead of treating his home support as a proxy for it.
Agreed after case management review: discharged on OPAT with weekly in-person infectious disease follow-up and an early two-week labs check, rather than either standard phone-based OPAT monitoring or prolonged inpatient completion.
Not agreed: whether a documented history of missed follow-up should be treated as a standing flag on any future OPAT candidacy decision for him, or whether this admission's stakes are enough on their own to change his engagement going forward — the hospitalist remains the most cautious of the three about how much the weekly-visit safeguard actually changes the underlying risk.